In a severe glaucoma patient, what percent reduction from Tmax should be targeted?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $25.99Unlock all

Boost your readiness for the Primary Open-Angle Glaucoma Test. Utilize flashcards and multiple-choice questions complete with hints and detailed explanations to enhance your understanding.

Multiple Choice

In a severe glaucoma patient, what percent reduction from Tmax should be targeted?

Explanation:
In glaucoma management, how much of a drop you aim for depends on how advanced the disease is. For severe glaucoma, you want a substantial reduction in intraocular pressure, typically more than 40% from the baseline maximum IOP (Tmax). This larger target helps protect the optic nerve when the risk of progression is greatest. For example, if Tmax is 28 mmHg, aiming for a reduction of more than 40% means targeting below about 17 mmHg. Achieving this often requires one or more therapies beyond a single medication, such as combination eye drops, laser therapy, or surgical options. Lower targets like 20–30% or 0–10% are generally considered less appropriate for severe disease because they may not reduce the risk of progression as effectively in these patients.

In glaucoma management, how much of a drop you aim for depends on how advanced the disease is. For severe glaucoma, you want a substantial reduction in intraocular pressure, typically more than 40% from the baseline maximum IOP (Tmax). This larger target helps protect the optic nerve when the risk of progression is greatest.

For example, if Tmax is 28 mmHg, aiming for a reduction of more than 40% means targeting below about 17 mmHg. Achieving this often requires one or more therapies beyond a single medication, such as combination eye drops, laser therapy, or surgical options.

Lower targets like 20–30% or 0–10% are generally considered less appropriate for severe disease because they may not reduce the risk of progression as effectively in these patients.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy